Literature DB >> 8892962

Possible role of the V3 domain of gp120 in resistance to an amphotericin B derivative (MS8209) blocking human immunodeficiency virus entry.

O Pleskoff1, N Sol, H Marrakchi, M Serlin, M Seman, M Alizon.   

Abstract

MS8209, an amphotericin B derivative blocking human immunodeficiency virus type 1 (HIV-1) entry after CD4 binding, neutralized the HIV-2 strains EHO and ROD10 but not ROD(CEM). In the V3 domain of gp120, ROD(CEM) differed from ROD10 at two positions (a threonine instead of an isoleucine at position 312 and an arginine instead of a glutamine at position 329), and drug resistance was conferred to HIV-1 by substitution of the ROD(CEM) V3 but not the ROD10 V3. V3 mutations may prevent the interaction of gp120 with MS8209 or modify the mechanism of virus entry, rendering it less accessible to neutralization.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8892962      PMCID： PMC190911     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  35 in total

1.  Derivatives of amphotericin inhibit infection with human immunodeficiency virus in vitro by different modes of action.

Authors:  J E Hansen; N M Witzke; C Nielsen; L R Mathiesen; L S Teglbjaerg; C M Nielsen; J O Nielsen
Journal:  Antiviral Res       Date:  1990-09       Impact factor: 5.970

2.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

Authors:  S Harada; Y Koyanagi; N Yamamoto
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

3.  Lymphadenopathy-associated virus type 2 in AIDS and AIDS-related complex. Clinical and virological features in four patients.

Authors:  F Brun-Vezinet; M A Rey; C Katlama; P M Girard; D Roulot; P Yeni; L Lenoble; F Clavel; M Alizon; S Gadelle
Journal:  Lancet       Date:  1987-01-17       Impact factor: 79.321

4.  Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by Simian immunodeficiency virus.

Authors:  P R Clapham; D Blanc; R A Weiss
Journal:  Virology       Date:  1991-04       Impact factor: 3.616

5.  Genome organization and transactivation of the human immunodeficiency virus type 2.

Authors:  M Guyader; M Emerman; P Sonigo; F Clavel; L Montagnier; M Alizon
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

6.  Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.

Authors:  M A Skinner; A J Langlois; C B McDanal; J S McDougal; D P Bolognesi; T J Matthews
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

Review 7.  How do the polyene macrolide antibiotics affect the cellular membrane properties?

Authors:  J Bolard
Journal:  Biochim Biophys Acta       Date:  1986-12-22

8.  Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene.

Authors:  T Shioda; J A Levy; C Cheng-Mayer
Journal:  Nature       Date:  1991-01-10       Impact factor: 49.962

9.  Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1.

Authors:  P S Linsley; J A Ledbetter; E Kinney-Thomas; S L Hu
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

10.  Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions.

Authors:  L N Callahan; M Phelan; M Mallinson; M A Norcross
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103
View more
  3 in total

1.  Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41.

Authors:  B Labrosse; O Pleskoff; N Sol; C Jones; Y Hénin; M Alizon
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Human immunodeficiency virus strains differ in their ability to infect CD4+ cells expressing the rat homolog of CXCR-4 (fusin).

Authors:  O Pleskoff; N Sol; B Labrosse; M Alizon
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

Review 3.  Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.

Authors:  Christopher J De Feo; Carol D Weiss
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.